Close menu




January 4th, 2022 | 07:00 CET

Unique opportunity in emerging markets: Nordex, Hong Lai Huat, NIO

  • Investments
Photo credits: pixabay.com

Risk appetite is returning to the market - the DAX recently reached the 16,000 point mark again. At the same time, the focus is once again increasingly on emerging markets. The experts at the fund company Jupiter Asset Management believe that the wind could soon turn for emerging markets. Nick Payne, Head of Strategy, Global Emerging Markets Focus at Jupiter Asset Management, sums up the situation: "If the vaccination programs in emerging countries catch up, their economies will open up again quickly, which could greatly support their equity markets." But what are the options for investing? We present three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: NORDEX SE O.N. | DE000A0D6554 , HONG LAI HUAT GROUP LIMITED | SG1EE1000009 , NIO INC.A S.ADR DL-_00025 | US62914V1061

Table of contents:


    Nordex: From Rostock to the whole world

    At first glance, the shares of the Rostock-based wind turbine manufacturer Nordex do not really fit into the picture when it comes to investments in emerging markets. But if you look at where the latest orders for the Rostock-based Company come from, the situation changes. The Company has landed orders in both Peru and Brazil in recent months. South America plays a significant role for Nordex, as the Company told researchanalyst.com a few weeks ago.

    For Nordex itself, business abroad is also important because the domestic market is still challenging due to slow approvals and lengthy procedures surrounding new wind power projects. Although the new German government has announced its intention to improve this area, it remains unclear how far such process optimizations can be implemented in the German bureaucratic jungle. The still low profitability is considered a global stumbling block for Nordex's business. The Delta4000 platform introduced some time ago is also no longer expected to have any significant margin effects, as the platform already plays a major role. The Nordex share is attractive due to climate change, but the Company has some tasks ahead of it.

    Hong Lai Huat: Unique opportunity in Cambodia

    The real estate project developer Hong Lai Huat from Singapore also has big tasks ahead of it. The Company operates four projects in Singapore and Cambodia. Cambodia, in particular, which is still heavily influenced by agriculture and tourism, is said to offer enormous growth potential. Only recently, Hong Lai Huat succeeded in obtaining approval from the Cambodian authorities to reallocate 100 million square meters of agricultural land for a gigantic project. In the future, fish farms and commercial areas for light industry and residential complexes are to be built there, in addition to modern livestock farming. GEM Comm analysts expect this project alone to generate noticeable returns in the coming years. However, investors should take into account that the project is extremely long-term and will not be fully implemented until 2040. Hong Lai Huat intends to develop the land step by step.

    The 9,818 square meter D'Seaview project is already completed, which was completed for USD 130 million in 2020. This building complex has 737 residential units and 67 commercial units in the Sihanouk Province. It is to be followed in 2023 by Royal Platinum, a similar but slightly larger project in Toul Kork District. Hong Lai Huat's stock is about 47% owned by the Ong family and has been trading within a sideways range in recent weeks. Although the real estate projects in Cambodia must seem speculative from the perspective of European investors, Hong Lai Huat brings the experience and know-how to make the projects successful. As travel between Singapore and Cambodia is possible again (Cambodia has a 100% vaccination rate among adults), sales of the apartments should also pick up again. Investors should keep an eye on the stock - where else is there an opportunity to invest in up-and-coming Cambodia?

    NIO: One swallow does not make a summer

    In a different category from Hong Lai Huat is the stock of NIO. The electric car maker from China is already well-known on the market and has already completed a large part of its revaluation. It is now a matter of getting off the ground in other countries and beating off competition from established brands. Nevertheless, NIO's customers could also become Hong Lai Huat's customers: Many people from China's emerging middle class treat themselves to apartments in surrounding countries. There, the cost of living is low and speculative profits beckon. While companies like NIO have great competition, the market for real estate in Cambodia is not yet as competitive. Those with a foot in the door usually play these advantages for longer. On the other hand, in the car market, established manufacturers are catching up. Even though the NIO share has recently shot up significantly, investors should invest with caution.


    There are many opportunities to invest in emerging markets. Even Nordex is benefiting from these regions. However, as vaccination coverage is key to economic recovery, countries like Cambodia, where 100% of eligible adults are vaccinated, may have advantages. Given the early stage of development of the agricultural country, which is also popular with tourists, Hong Lai Huat's stock could be a long-term opportunity. However, the stock remains highly speculative.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read